Vaxcyte (NASDAQ:PCVX) EVP Sells $79,399.68 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,334 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68. Following the completion of the transaction, the executive vice president owned 145,435 shares in the company, valued at $8,656,291.20. The trade was a 0.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Trading Down 1.4%

Shares of PCVX traded down $0.85 during midday trading on Wednesday, reaching $59.51. 1,195,242 shares of the company were exchanged, compared to its average volume of 1,369,661. The stock has a 50-day moving average price of $58.41 and a 200-day moving average price of $56.32. The company has a market cap of $8.86 billion, a price-to-earnings ratio of -7.80 and a beta of 1.22. Vaxcyte, Inc. has a 1-year low of $30.81 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the company posted ($1.22) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of PCVX. NEXTBio Capital Management LP purchased a new position in Vaxcyte in the fourth quarter valued at about $4,406,000. Norges Bank purchased a new stake in Vaxcyte during the 4th quarter worth approximately $56,703,000. Bank of America Corp DE increased its holdings in Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after purchasing an additional 515,209 shares during the last quarter. Elmind Capital LP acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $13,450,000. Finally, Eventide Asset Management LLC raised its position in shares of Vaxcyte by 141.8% in the 4th quarter. Eventide Asset Management LLC now owns 917,115 shares of the company’s stock valued at $42,313,000 after purchasing an additional 537,785 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PCVX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.